Hycamtin 0.25mg. 1mg Capsule
PDF Leaflet Revision Date: 9 May 2012
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of small cell lung carcinoma.
Dosage (summary)
2.3 mg/mu00b2 daily for 5 days every 21 days.
Onset of Action / Duration
Onset: 1-2 hours, Duration: 3-6 hours
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Enhanced myelosuppression with cytotoxic agents
- Increased exposure with ABCB1/ABCG2 inhibitors
Contraindications
- Severe hypersensitivity to topotecan
- Pregnancy
- Severe bone marrow depression
Common side effects
- Diarrhoea
- Nausea
- Vomiting
- Fatigue
- Neutropenia
Counselling Points
- Avoid pregnancy during treatment
- Report signs of infection or severe diarrhoea
- Do not chew or crush capsules
Serious warnings
- Severe myelosuppression
- Risk of neutropenic colitis
- Monitor blood counts regularly
Important Disclaimer
The Hycamtin 0.25mg. 1mg Capsule professional information leaflet below is the property of Sandoz and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
